Evidence map›Paper›PMID 41605920›Full record

ArticleNature communications2026

Leveraging glucan-induced trained immunity for the epigenetic and metabolic rewiring of macrophages to enhance colorectal cancer vaccine response.

Firas Hamdan, Sara Gandolfi, Federica D'Alessio, Yvonne Giannoula, Julia Kolikova, Manlio Fusciello, Elisa Zaghen, Alessandra Napolano, Salvatore Russo, Ozan Izci and 15 more

Registry-linked trialAbstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07510308 (A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Antitumor Activity of MSH2-/- Tumor Cell Vaccines in Patients With Advanced pMMR Colorectal Cancer.), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07510308 phase1recruitingnot on this map

A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Antitumor Activity of MSH2-/- Tumor Cell Vaccines in Patients With Advanced pMMR Colorectal Cancer.

TypeinterventionalSponsorWest China HospitalRan2026 to 2027Enrolled9ConditionspMMR/MSS Advanced Colorectal CancerArmsLow Dose MSH2-/- tumor cell vaccine, Medium Dose MSH2-/- tumor cell vaccine, High dose MSH2-/- tumor cell vaccine
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. BCG HSP70 Reprograms Macrophages via Central Trained Immunity to Suppress Prostate Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Heat-killedFrontiers in immunology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Firas HamdanDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0003-4678-7382
Sara Gandolfi *iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.ORCID http://orcid.org/0000-0001-6207-4433
Federica D'Alessio *Drug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.
Yvonne GiannoulaDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0003-4265-5411
Julia KolikovaiCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
Manlio FuscielloDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-7166-3018
Elisa ZaghenDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0009-0006-6665-296X
Alessandra NapolanoDepartment of Molecular Medicine and Medical Biotechnology, Naples University "Federico II", S. Pansini 5, Naples, Italy.
Salvatore RussoDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.
Ozan IzciDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.
Paolo BottegaDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.
Jacopo ChiaroDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0001-6577-2691
Kirsi-Marja AlanenBiochemistry/Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0009-0002-0068-6850
Gabriella AntignaniDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.
Michaela FeodoroffDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-6094-9838
Virpi StigzeliusDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.
Milda SakalauskaiteDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.
Janita SandbergDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.
Anni I NieminenHelsinki Metabolomics Center, Stem Cell and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0001-8999-6040
Nicola ZambranoDepartment of Molecular Medicine and Medical Biotechnology, Naples University "Federico II", S. Pansini 5, Naples, Italy.
Ove ErikssonBiochemistry/Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Satu MustjokiiCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.ORCID http://orcid.org/0000-0002-0816-8241
Toni T SeppäläiCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
Mikaela GrönholmDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland.
Vincenzo CerulloDrug Research Program (DRP) ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, Viikinkaari 5E, University of Helsinki, Helsinki, Finland. vincenzo.cerullo@helsinki.fi.ORCID http://orcid.org/0000-0003-4901-3796

Funding

Jane ja Aatos Erkon Säätiö (Jane and Aatos Erkko Foundation) 4705796
6 · The paper itself

Abstract

Colorectal cancer (CRC) remains refractory to most immunotherapies, with cancer vaccines failing due to an immunosuppressive tumor microenvironment. Here, we show that β-glucan-induced trained immunity overcomes these barriers by reprogramming macrophages through H3K4me3-dependent epigenetic modifications and metabolic rewiring. In female mice vaccinated with peptide-coated adenovirus-based vaccine PeptiCrad, training enhances glycolysis with creatine metabolism sustaining CXCL9/10 production, enabling macrophages to recruit NK cells via CXCR3. In turn, NK cells produce CCL5, driving cDC1 infiltration and antigen presentation, which together amplify effector memory CD8⁺ T cell responses. Moreover, with human peripheral blood mononuclear cells and CRC patient-derived organoids, trained macrophages boost NK migration, antigen-specific T cell activation, and tumor killing. These findings highlight trained immunity as a powerful adjuvant to reinvigorate colorectal cancer vaccination.

Indexed as

beta-GlucansCancer VaccinesColorectal NeoplasmsEpigenesis, GeneticMacrophagesAnimalsCD8-Positive T-LymphocytesCell Line, TumorChemokine CCL5FemaleGlycolysisHumansKiller Cells, NaturalLymphocyte ActivationMetabolic ReprogrammingMicebeta-GlucansCancer VaccinesChemokine CCL5Cxcr3 protein, mouseReceptors, CXCR3

Identifiers

PMID41605920
PMCPMC12914026

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.